Back
Open Access

Real-world burden of heart failure with reduced ejection fraction and dapagliflozin use at 2 years after approval in 9 countries from Central Eastern Europe and Baltic Area: EVOLUTION-HF CEE-BA study

Session: Digitoxin and other therapeutic strategic advances
Topic: Pharmacotherapy
Speaker: Professor I. Gruev (Sofia, BG)
Event: Heart Failure 2025

Congress Presentation

Add to my library

Like

About the speaker

Professor Ivan Gruev

National Transport Hospital Tzar Boris III, Sofia (Bulgaria)
1 presentation
0 follower

4 more presentations in this session

Effects of glucagon like peptide 1 receptor agonist initiation in patients with heart failure and reduced ejection fraction and implantable cardiac devices

Speaker: Doctor P. Marques (Porto, PT)

Access
Abstract
Like
Thumbnail

Hemoglobin, hematocrit and heart failure: the SGLT2 inhibitor connection

Speaker: Doctor D. Ferreira (Lisbon, PT)

Access
Abstract
Like
Thumbnail

Safety and efficacy of early initiation of mineralocorticoid receptor antagonists in patients with worsening heart failure: a meta-analysis of randomized controlled trials

Speaker: Doctor R. Laborante (Rome, IT)

Access
Abstract
Like
Thumbnail

Socioeconomic disparities in guideline directed medical therapy for HFrEF: a population-based cohort study using electronic health records (the Netherlands)

Speaker: Ms J. van Eijk (Utrecht, NL)

Access
Abstract
Like
Thumbnail

Access the full session

Digitoxin and other therapeutic strategic advances

Speakers: Professor I. Gruev, Doctor P. Marques, Doctor D. Ferreira, Doctor R. Laborante, Ms J. van Eijk
Access
Like
Thumbnail

About the event

Image

Heart Failure 2025

17 May - 20 May 2025

Sessions Presentations

Congress
logo Image

ESC 365 is supported by

logo Bristol Myers Squibb Explore sponsored resources
logo Novartis Explore sponsored resources
logo Novo Nordisk Explore sponsored resources